Produced by photosynthesis, oxygen (O2) is a fundamentally important gas in biological systems, playing roles as a terminal electron receptor in respiration and in host defence through the creation of reactive oxygen species (ROS). Hydrogen (H2) plays a role in metabolism for some organisms, such as at thermal vents and in the gut environment, but has a role in controlling growth and development, and in disease states, both in plants and animals. It has been suggested as a medical therapy and for enhancing agriculture. However, the exact mode of action of H2 in biological systems is not fully established. Furthermore, there is an interrelationship between O2 and H2 in organisms. These gases may influence each other’s presence in solution, and may both interact with the same cellular components, such as haem prosthetic groups. It has also been suggested that H2 may affect the structures of some proteins, such as globins, with possible effects on O2 movement in organisms. Lastly, therapies may be based on supplying O2 and H2 together, such as with oxyhydrogen. Therefore, the relationship regarding how biological systems perceive and respond to both O2 and H2, and the interrelationship seen are worth considering, and will be discussed here.
{"title":"An Interplay of Gases: Oxygen and Hydrogen in Biological Systems","authors":"Grace Russell, Jennifer May, John T. Hancock","doi":"10.3390/oxygen4010003","DOIUrl":"https://doi.org/10.3390/oxygen4010003","url":null,"abstract":"Produced by photosynthesis, oxygen (O2) is a fundamentally important gas in biological systems, playing roles as a terminal electron receptor in respiration and in host defence through the creation of reactive oxygen species (ROS). Hydrogen (H2) plays a role in metabolism for some organisms, such as at thermal vents and in the gut environment, but has a role in controlling growth and development, and in disease states, both in plants and animals. It has been suggested as a medical therapy and for enhancing agriculture. However, the exact mode of action of H2 in biological systems is not fully established. Furthermore, there is an interrelationship between O2 and H2 in organisms. These gases may influence each other’s presence in solution, and may both interact with the same cellular components, such as haem prosthetic groups. It has also been suggested that H2 may affect the structures of some proteins, such as globins, with possible effects on O2 movement in organisms. Lastly, therapies may be based on supplying O2 and H2 together, such as with oxyhydrogen. Therefore, the relationship regarding how biological systems perceive and respond to both O2 and H2, and the interrelationship seen are worth considering, and will be discussed here.","PeriodicalId":516952,"journal":{"name":"Oxygen","volume":"321 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139895068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Ektesabi, Julia Simone, C. Vaswani, Greaton W. Tan, Yanbo Wang, Jacqueline L. Pavelick, Xiao Wu, Janice Tai, Sahil Gupta, James N Tsoporis, Claudia C. dos Santos
Background: Sepsis is a severe and life-threatening condition triggered by a dysregulated response to infection, leading to organ failure and, often, death. The syndrome is expensive to treat, with survivors frequently experiencing reduced quality of life and enduring various long-term disabilities. The increasing understanding of RNA, RNA biology, and therapeutic potential offers an unprecedented opportunity to develop innovative therapy. Objective: This study is a scoping review focusing on pre-clinical studies of microRNA (miRNA)-based therapies for sepsis. Methodology: A scoping review. The search strategy identified papers published in PubMed until 15 October 2023, using the keywords (microRNA) AND (sepsis) AND (animal model). Inclusion criteria included papers that used either gain- or loss-of-function approaches, excluding papers that did not focus on microRNAs as therapy targets, did not include animal models, did not show organ failure-specific assessments, and focused on microRNAs as biomarkers. The PRISMA-ScR guideline was used in this study. Results: A total of 199 articles were identified that featured the terms “microRNA/miRNA/miR”, “Sepsis”, and “animal model”. Of these, 51 articles (25.6%) employed miRNA-based therapeutic interventions in animal models of sepsis. Of these, 15 studies extended their inquiry to include or reference human clinical data. Key microRNAs of interest and their putative mechanisms of action in sepsis are highlighted. Conclusions: The body of work examined herein predominantly addresses various dimensions of sepsis-induced organ dysfunction, supporting the emerging role of miRNAs as potential therapeutic candidates. However, nearly 5% of papers on miR-based therapy have been retracted over the past 5 years, raising important concerns regarding the quality and complexity of the biology and models for assessing therapeutic potential.
{"title":"Pre-Clinical Studies of MicroRNA-Based Therapies for Sepsis: A Scoping Review","authors":"A. Ektesabi, Julia Simone, C. Vaswani, Greaton W. Tan, Yanbo Wang, Jacqueline L. Pavelick, Xiao Wu, Janice Tai, Sahil Gupta, James N Tsoporis, Claudia C. dos Santos","doi":"10.3390/oxygen4010002","DOIUrl":"https://doi.org/10.3390/oxygen4010002","url":null,"abstract":"Background: Sepsis is a severe and life-threatening condition triggered by a dysregulated response to infection, leading to organ failure and, often, death. The syndrome is expensive to treat, with survivors frequently experiencing reduced quality of life and enduring various long-term disabilities. The increasing understanding of RNA, RNA biology, and therapeutic potential offers an unprecedented opportunity to develop innovative therapy. Objective: This study is a scoping review focusing on pre-clinical studies of microRNA (miRNA)-based therapies for sepsis. Methodology: A scoping review. The search strategy identified papers published in PubMed until 15 October 2023, using the keywords (microRNA) AND (sepsis) AND (animal model). Inclusion criteria included papers that used either gain- or loss-of-function approaches, excluding papers that did not focus on microRNAs as therapy targets, did not include animal models, did not show organ failure-specific assessments, and focused on microRNAs as biomarkers. The PRISMA-ScR guideline was used in this study. Results: A total of 199 articles were identified that featured the terms “microRNA/miRNA/miR”, “Sepsis”, and “animal model”. Of these, 51 articles (25.6%) employed miRNA-based therapeutic interventions in animal models of sepsis. Of these, 15 studies extended their inquiry to include or reference human clinical data. Key microRNAs of interest and their putative mechanisms of action in sepsis are highlighted. Conclusions: The body of work examined herein predominantly addresses various dimensions of sepsis-induced organ dysfunction, supporting the emerging role of miRNAs as potential therapeutic candidates. However, nearly 5% of papers on miR-based therapy have been retracted over the past 5 years, raising important concerns regarding the quality and complexity of the biology and models for assessing therapeutic potential.","PeriodicalId":516952,"journal":{"name":"Oxygen","volume":"75 48","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140486253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Athanasiadis, Theodoros G. Chatzimitakos, Ioannis Makrygiannis, Dimitris Kalompatsios, Eleni Bozinou, S. Lalas
A member of the Verbenaceae family, Aloysia citrodora, or lemon verbena, is a medicinal herb with antioxidant compounds. The aim of this study was to develop a green, optimized method for the bioactive compound (carotenoids, ascorbic acid, and polyphenols) extraction from lemon verbena leaves through response surface methodology (RSM). The bioactive compound recovery was shown to be significantly affected by the extraction technique (both with pulsed electric field and ultrasound-assisted extraction), along with an extraction solvent, based on partial least squares analysis. Consequently, the maximum polyphenol yield required a double-assisted extraction with a relatively low extraction duration (60 min) at a high temperature (80 °C), with a moderate-polarity extraction solvent (50% v/v ethanol). With the optimized method, the total polyphenol content (TPC) was measured at 175.03 mg gallic acid equivalents/g, whereas chromatographic analysis revealed that verbascoside was the most prevalent polyphenol (132.61 mg/g). The optimum extract provided a high antioxidant capacity through the measurements of FRAP (1462.17 μmol ascorbic acid equivalents (AAE)/g), DPPH (1108.91 μmol AAE/g), and H2O2 (1662.93 μmol AAE/g). Total carotenoids were measured at 499.61 μg/g, with ascorbic acid at 8.36 μg/g. Correlation analyses revealed a negative correlation of the latter compound with color coordinates. This study highlights the potential of lemon verbena leaves to be used in pharmaceutical and food industries.
{"title":"Antioxidant-Rich Extracts from Lemon Verbena (Aloysia citrodora L.) Leaves through Response Surface Methodology","authors":"V. Athanasiadis, Theodoros G. Chatzimitakos, Ioannis Makrygiannis, Dimitris Kalompatsios, Eleni Bozinou, S. Lalas","doi":"10.3390/oxygen4010001","DOIUrl":"https://doi.org/10.3390/oxygen4010001","url":null,"abstract":"A member of the Verbenaceae family, Aloysia citrodora, or lemon verbena, is a medicinal herb with antioxidant compounds. The aim of this study was to develop a green, optimized method for the bioactive compound (carotenoids, ascorbic acid, and polyphenols) extraction from lemon verbena leaves through response surface methodology (RSM). The bioactive compound recovery was shown to be significantly affected by the extraction technique (both with pulsed electric field and ultrasound-assisted extraction), along with an extraction solvent, based on partial least squares analysis. Consequently, the maximum polyphenol yield required a double-assisted extraction with a relatively low extraction duration (60 min) at a high temperature (80 °C), with a moderate-polarity extraction solvent (50% v/v ethanol). With the optimized method, the total polyphenol content (TPC) was measured at 175.03 mg gallic acid equivalents/g, whereas chromatographic analysis revealed that verbascoside was the most prevalent polyphenol (132.61 mg/g). The optimum extract provided a high antioxidant capacity through the measurements of FRAP (1462.17 μmol ascorbic acid equivalents (AAE)/g), DPPH (1108.91 μmol AAE/g), and H2O2 (1662.93 μmol AAE/g). Total carotenoids were measured at 499.61 μg/g, with ascorbic acid at 8.36 μg/g. Correlation analyses revealed a negative correlation of the latter compound with color coordinates. This study highlights the potential of lemon verbena leaves to be used in pharmaceutical and food industries.","PeriodicalId":516952,"journal":{"name":"Oxygen","volume":"253 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140500242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：